Table 1

Patient characteristics at study entry (all eligible patients, n = 169)

CharacteristicValue
Sex, female/male (%) 28/141 (17/83) 
Age, y 51 (27-60) 
IGHV unfavorable (%) 87/91 (68) 
    Unmutated* (%) 84/129 (65) 
    V3-21 mutated (%) 4/129 (3) 
FISH karyotype (hierarchical model)  
    17p- ± others (%) 4/160 (2.5) 
    11q- ± others (except 17p-) (%) 40/160 (25) 
    +12 ± others (except 17p-, 11q-) (%) 20/160 (12.5) 
    13q- only (%) 48/160 (30) 
    Others (%) 20/160 (12.5) 
    Normal FISH karyotype (%) 28/160 (17) 
Binet stage A, B, C (%) 26, 94, 46 (16, 56, 28) 
Time from diagnosis, mo 13 (0-156) 
Chemotherapy naïve (%) 152/167 (91) 
Serum thymidine kinase > 7 U/L (%) 97/115 (84) 
β2M > 3.5 mg/L (%) 47/115 (41) 
Lymphocyte doubling time < 12 mo (%) 55/104 (53) 
White blood count > 50/nL (%) 92/162 (57) 
CharacteristicValue
Sex, female/male (%) 28/141 (17/83) 
Age, y 51 (27-60) 
IGHV unfavorable (%) 87/91 (68) 
    Unmutated* (%) 84/129 (65) 
    V3-21 mutated (%) 4/129 (3) 
FISH karyotype (hierarchical model)  
    17p- ± others (%) 4/160 (2.5) 
    11q- ± others (except 17p-) (%) 40/160 (25) 
    +12 ± others (except 17p-, 11q-) (%) 20/160 (12.5) 
    13q- only (%) 48/160 (30) 
    Others (%) 20/160 (12.5) 
    Normal FISH karyotype (%) 28/160 (17) 
Binet stage A, B, C (%) 26, 94, 46 (16, 56, 28) 
Time from diagnosis, mo 13 (0-156) 
Chemotherapy naïve (%) 152/167 (91) 
Serum thymidine kinase > 7 U/L (%) 97/115 (84) 
β2M > 3.5 mg/L (%) 47/115 (41) 
Lymphocyte doubling time < 12 mo (%) 55/104 (53) 
White blood count > 50/nL (%) 92/162 (57) 
*

Unmutated (> 98% homology to germline).

At initiation of first-line treatment.

or Create an Account

Close Modal
Close Modal